

## **Asthma: diagnosis and chronic management in children ≤11 years**

### **Key Facts**

- Asthma in children can be challenging to diagnose and requires careful history of previous treatments for respiratory symptoms.
- Children who are usually well and **ONLY** wheeze when they have a viral illness should **NOT** be diagnosed with asthma. They have viral wheeze. Inhaled short acting beta-agonists (salbutamol) may help.

### **Clinical Presentation**

Breathlessness, wheeze, chest tightness, or cough that is:

- ✓ Worse at night and early morning or with a viral infection
- ✓ Comes with/after exercise
- ✓ Comes with allergen exposure or cold air.

### **Investigation**

- ✓ A good history is more important than any test. Focus on the features above (Xrays and blood tests only helpful if another condition suspected)
- ✓ Spirometry is the gold standard for diagnosis, but rarely necessary and currently not available in Kijabe.
- ✓ Trial of treatment with SABA (as needed) and 8 weeks of inhaled steroids can be used to confirm the diagnosis.

### **Management**

**Transfer patient to Casualty if features of Asthma exacerbation: unstable vitals, patient can't complete sentences, difficulty in breathing with use of accessory muscles.**

### **Management of chronic stable asthma**

See attached GINA 2021 stepwise management figures on page 2 and 3 for children under 5 years and 6-11 years respectively.

- ✓ Seek OPD consultant advice before escalating to step 3.
- ✓ A spacer device should **always** be used with an aerosol/MDI inhaler. Children under 10 years cannot coordinate their breathing well enough to use any other device. Use a bottle if they can't afford spacer.
- ✓ Check inhaler/spacer technique before escalating to the next step (see separate protocol on 'Inhaler technique in asthma and COPD').
- ✓ Check and prescribe recommended inhaler doses in mcg and **NOT** in puffs only.

### **References:**

2019 Primary Care International COPD Clinical Guide


Global Initiative for Asthma (GINA) 2021 Guideline



## Children 5 years and younger

### Personalized asthma management:

Assess, Adjust, Review response



### Asthma medication options:

Adjust treatment up and down for individual child's needs

#### PREFERRED CONTROLLER CHOICE

Other controller options

#### RELIEVER

#### CONSIDER THIS STEP FOR CHILDREN WITH:


	STEP 1	STEP 2	STEP 3	STEP 4
		Daily low dose inhaled corticosteroid (ICS) (see table of ICS dose ranges for pre-school children)	Double 'low dose' ICS	Continue controller & refer for specialist assessment
		Daily leukotriene receptor antagonist (LTRA), or intermittent short courses of ICS at onset of respiratory illness	Low dose ICS + LTRA Consider specialist referral	Add LTRA, or increase ICS frequency, or add intermittent ICS
	As-needed short-acting $\beta_2$ -agonist			
	Infrequent viral wheezing and no or few interval symptoms	Symptom pattern not consistent with asthma but wheezing episodes requiring SABA occur frequently, e.g. $\geq 3$ per year. Give diagnostic trial for 3 months. Consider specialist referral. Symptom pattern consistent with asthma, and asthma symptoms not well-controlled or $\geq 3$ exacerbations per year.	Asthma diagnosis, and asthma not well-controlled on low dose ICS  Before stepping up, check for alternative diagnosis, check inhaler skills, review adherence and exposures	Asthma not well-controlled on double ICS



## Children 6-11 years

### Personalized asthma management:

Assess, Adjust, Review



### Asthma medication options:

Adjust treatment up and down for individual child's needs

**PREFERRED CONTROLLER**  
to prevent exacerbations and control symptoms

Other controller options

### RELIEVER

	STEP 1	STEP 2	STEP 3	STEP 4	STEP 5
<b>PREFERRED CONTROLLER</b>	Low dose ICS taken whenever SABA taken	Daily low dose inhaled corticosteroid (ICS) (see table of ICS dose ranges for children)	Low dose ICS-LABA, OR medium dose ICS, OR very low dose* ICS-formoterol maintenance and reliever (MART)	Medium dose ICS-LABA, OR low dose† ICS-formoterol maintenance and reliever therapy (MART). Refer for expert advice	Refer for phenotypic assessment ± higher dose ICS-LABA or add-on therapy, e.g. anti-IgE
<b>Other controller options</b>	Consider daily low dose ICS	Daily leukotriene receptor antagonist (LTRA), or low dose ICS taken whenever SABA taken	Low dose ICS + LTRA	Add tiotropium or add LTRA	Add-on anti-IL5, or add-on low dose OCS, but consider side-effects
<b>RELIEVER</b>	As-needed short-acting beta2-agonist (or ICS-formoterol reliever for MART as above)				